Incyte vs Viatris
Incyte (INCY), health care, and Viatris (VTRS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Incyte is worth $24.3B on the stock market and Viatris $23.4B: Incyte is valued at 4% more. Incyte's operating margin in its latest fiscal year was 29.5% and Viatris's -18.6%. Over the past year Incyte's share price has moved +15.8% and Viatris's +93.7%.
Key facts
- Incyte market value
- $24.3B
- Viatris market value
- $23.4B
- Incyte P/E
- 61.4
- Incyte revenue
- $5.1BFY to 2025-12-31
- Viatris revenue
- $14.3BFY to 2025-12-31
- Superinvestors holding both
- 3
Market values as of .
| Measure | Incyte | Viatris |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $24.3Bhigher | $23.4Blower |
| Revenue | $5.1Blower | $14.3Bhigher |
| Earnings | $1.3Bhigher | -$3.5Blower |
| Employees | 2,844lower | 30,000higher |
| Total assets | $7Blower | $37.2Bhigher |
| Valuation | ||
| P/E | 61.4 | — |
| P/S | 4.7higher | 1.6lower |
| P/B | 4.3higher | 1.7lower |
| Dividend yield | 0.00%lower | 2.31%higher |
| Profitability | ||
| Operating margin | 29.5%higher | -18.6%lower |
| Balance sheet | ||
| Net assets | $5.2Blower | $14.7Bhigher |
| Total liabilities | $1.8Blower | $22.5Bhigher |
| Total debt | — | $14.4B |
| Cash on hand | $3.1Bhigher | $1.3Blower |
| Price change | ||
| Today | -0.98%higher | -1.40%lower |
| 1 year | +15.8%lower | +93.7%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (3)
- Harry Burn2.3% / 2.5%
- Josef Lakonishok0.9% / 0.3%
- Joel Greenblatt0.2% / 0.2%
Incyte only (5)
Viatris only (6)
- Christopher Davis5.5%
- Anthony Bozza3.2%
- Larry Robbins3.1%
- Bill Miller (founder)2.8%
- David Einhorn1.1%
- Louis Bacon0.3%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Incyte / Viatris). Who owns INCY · Who owns VTRS
More on Incyte
Further comparisons
Incyte against its closest peers
Viatris against its closest peers
Learn
Questions and answers
Which is bigger, Incyte or Viatris?
By market value, Incyte is the larger: $24.3B against $23.4B for Viatris. By revenue in its latest fiscal year, Viatris is the larger: $14.3B against $5.1B for Incyte.
Which has the higher operating margin?
Incyte: 29.5%, against -18.6% for Viatris. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Viatris: 2.31%, against 0.00% for Incyte. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Incyte and Viatris?
In their latest 13F filings, Harry Burn, Josef Lakonishok and Joel Greenblatt hold both.
Cite this page
Funkfolio, “Incyte vs Viatris”, data as of 18 November 2026. https://funkfolio.com/compare/incy-vs-vtrs
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.